Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey L Uy

Showing results (11-20 of 146) with videos related to

Pageof 15
Sort By:
Blood|December 4, 2023
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to actionVijaya Raj Bhatt, Geoffrey L Uy, Heidi D Klepin
Bulletin of the American College of Surgeons|September 19, 2017
Junior investigators: Get engaged in the Alliance for Clinical Trials in OncologyGeoffrey L Uy, Matthew H G Katz, Judy C Boughey
Nature Reviews. Drug Discovery|January 31, 2009
PlerixaforJohn F DiPersio, Geoffrey L Uy, Uma Yasothan, et al.
Haematologica|October 18, 2006
The activity and toxicity of low dose clofarabine against relapsed or refractory myelomaGeoffrey L Uy, Michael H Tomasson, Alisa Ruddell, et al.
Science Translational Medicine|June 7, 2013
Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host diseaseGerald P Morris, Geoffrey L Uy, David Donermeyer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022Gregory W Roloff, Olatoyosi Odenike, Ashish Bajel, et al.
Investigational New Drugs|February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemiaGeoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Journal of Hematology & Oncology|July 14, 2021
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AMLJorge E Cortes, Tara L Lin, Geoffrey L Uy, et al.
Blood|July 22, 2010
A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemiaGeoffrey L Uy, Andrew A Lane, John S Welch, et al.
Leukemia & Lymphoma|February 6, 2019
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsIoannis Papageorgiou, Michael R Loken, Lisa Eidenschink Brodersen, et al.
Pageof 15

Showing results (11-20 of 146) with videos related to

Sort By:
Pageof 15
Blood|December 4, 2023
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to actionVijaya Raj Bhatt, Geoffrey L Uy, Heidi D Klepin
Bulletin of the American College of Surgeons|September 19, 2017
Junior investigators: Get engaged in the Alliance for Clinical Trials in OncologyGeoffrey L Uy, Matthew H G Katz, Judy C Boughey
Nature Reviews. Drug Discovery|January 31, 2009
PlerixaforJohn F DiPersio, Geoffrey L Uy, Uma Yasothan, et al.
Haematologica|October 18, 2006
The activity and toxicity of low dose clofarabine against relapsed or refractory myelomaGeoffrey L Uy, Michael H Tomasson, Alisa Ruddell, et al.
Science Translational Medicine|June 7, 2013
Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host diseaseGerald P Morris, Geoffrey L Uy, David Donermeyer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022Gregory W Roloff, Olatoyosi Odenike, Ashish Bajel, et al.
Investigational New Drugs|February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemiaGeoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Journal of Hematology & Oncology|July 14, 2021
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AMLJorge E Cortes, Tara L Lin, Geoffrey L Uy, et al.
Blood|July 22, 2010
A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemiaGeoffrey L Uy, Andrew A Lane, John S Welch, et al.
Leukemia & Lymphoma|February 6, 2019
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsIoannis Papageorgiou, Michael R Loken, Lisa Eidenschink Brodersen, et al.
Pageof 15